Investors

A young success story open to anyone

Just five years after its founding, Cantourage has quickly established itself as a market leader in the European medical cannabis sector, consistently achieving substantial revenue growth year after year. By leveraging its asset-light strategy and cost efficiency, Cantourage achieved break-even in 2023

In preparation for cannabis legalisation in Germany, Cantourage went public in Autumn of 2022 to enable small and institutional investors  to be part of a global growth industry. The company is listed on the Frankfurt Stock Exchange under the ticker “HIGH”.
Just five years after its founding, Cantourage has quickly established itself as a market leader in the European medical cannabis sector, consistently achieving substantial revenue growth year after year. By leveraging its asset-light strategy and cost efficiency, Cantourage achieved break-even in 2023
In preparation for cannabis legalisation in Germany, Cantourage went public in Autumn of 2022 to enable small and institutional investors  to be part of a global growth industry. The company is listed on the Frankfurt Stock Exchange under the ticker “HIGH”.

So, what does Cantourage do?

Cantourage sources cannabis from around the world, imports it to its European manufacturing hubs to produce pharmaceutical cannabis medicines, and distributes them throughout Europe's fastest growing medical cannabis markets.

Cantourage helps cultivators access Europe’s rapidly expanding medical cannabis markets. So far, Cantourage has signed over 60 long-term contracts with cannabis growers from 18 countries.

Cantourage implemented a revenue-sharing model which allows Cantourage to avoid investing in costly cultivation facilities and long-term purchase commitments, thereby minimising the company's working capital risk.
Cantourage sources cannabis from around the world, imports it to its European manufacturing hubs to produce pharmaceutical cannabis medicines, and distributes them throughout Europe's fastest growing medical cannabis markets.

Cantourage helps cultivators access Europe’s rapidly expanding medical cannabis markets. So far, Cantourage has signed over 60 long-term contracts with cannabis growers from 18 countries.
Cantourage implemented a revenue-sharing model which allows Cantourage to avoid investing in costly cultivation facilities and long-term purchase commitments, thereby minimising the company's working capital risk.

Based at the heart of Europe's cannabis progress

Upon arrival in Germany, Cantourage handles all necessary processes to transform imported cannabis raw material into prescription medicines. For cannabis flowers, these steps include trimming, microbiological load reduction, packaging and labelling, testing, market release, warehousing, and fulfilment. All these processes are carried out at Cantourage’s production facility in Southern Germany, along with its associated laboratories and service providers.
Upon arrival in Germany, Cantourage handles all necessary processes to transform imported cannabis raw material into prescription medicines.
For cannabis flowers, these steps include trimming, microbiological load reduction, packaging and labelling, testing, market release, warehousing, and fulfilment. All these processes are carried out at Cantourage’s production facility in Southern Germany, along with its associated laboratories and service providers.
Since May of 2024, Cantourage has an additional production partner in Portugal to further stabilise the supply chain and security of supply for all of Europe.

Supplying markets as they open

Once manufactured, the products are shipped to pharmacies throughout Cantourage’s home market Germany, as well as, to the UK via its subsidiary Cantourage UK. Additionally, Cantourage distributes  products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.
Once manufactured, the products are shipped to pharmacies throughout Cantourage’s home market Germany, as well as, to the UK via its subsidiary Cantourage UK.
Additionally, Cantourage distributes  products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.
Additionally, Cantourage has sold products to five more European markets: Austria, Switzerland, Poland, Czech Republic and Denmark.

Spearheading all product categories

In the cannabis flower market, Cantourage is proud to offer the most diversified product portfolio in Europe, with its growers supplying a wide range of different cultivars from value products to craft cannabis – allowing Cantourage to quickly cater to changing patients’ needs and market demands. Since German cannabis legalisation, Cantourage has been witnessing a massive influx in medical cannabis demand, with revenue in April 2024 growing by around 160% compared to the same month of the previous year.
Besides cannabis flowers, Cantourage is also well positioned in other market segments such as extracts and active ingredients. In the German Dronabinol (= pure THC) market, Cantourage has asserted itself amidst experienced big pharma competition and today is one of the market leaders in Europe.

Easing patient access

In both Germany (“Telecan”) and the UK (“Cantourage Clinic”), Cantourage operates its own (telehealth) medical platform to make it easier for people to access medicinal cannabis. Patients can openly discuss cannabis treatment with a doctor - without fear of stigmatisation.

The process is very simple: after registering online, including completing a questionnaire, patients can make an initial appointment and receive their cannabis prescription, which is then sent to a pharmacy of the patient’s choice. In Germany, in addition to an online consultation, it is also possible for patients to visit the expert doctors at their practice locations.

Shares

Stock chart

PRICE – HIGH.F -

Download
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Basic information

ISIN

DE000A3DSV01

Segment

Scale

Ticker Symbol 

HIGH

Class of shares

Bearer shares

Trading venues 

XETRA, Frankfurt (Scale), Open Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

Financial year  

1 January to 31 December

LEI

3912003NCTLO6YHA9V48

Specialist

WOLFGANG STEUBING AG

Designated Sponsor

Hauck Aufhäuser /mwb fairtrade Wertpapierhandelsbank, both Frankfurt am Main

Number of shares 

12,467,479

Share capital in EUR

12 467 479,00

Market

Open Market

Securities identification number

A3DSV0

First trading day

11/11/2022

we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis
we love cannabis

Annual General Meeting

Here you will find detailed information and documents on the Annual General Meeting of Cantourage Group SE, which will take place on Wednesday, 26 June 2024, at 1:00 p.m. on the premises of palisa.de GmbH (top floor) at Palisadenstr. 48, 10243 Berlin.

Financial calendar & newsletter

2024
2023
2022

Interested in our IR newsletter? Simply enter your details below!

Hello, my name is
Name required
. I am a(n)
Investor
from
Input required
and like to get in touch about:
You can reach me via e-mail at
Invalid email
!

Thank you for the message!

We're rolling up our sleeves
to craft a response that is as smooth as our finest strains.

Stay tuned!

Oops! Something went wrong while submitting the form.
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations
contact Investor relations